文献速递真菌感染艾滋病与性传播感染

氟康唑联合氟胞嘧啶治疗非洲隐球菌性脑膜炎的多国成本效果分析

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究基于ACTA试验及赞比亚站点成本数据,比较氟康唑联合氟胞嘧啶与氟康唑单药治疗非洲隐球菌性脑膜炎的成本效果。联合方案每例平均费用847美元,10周死亡率35.1%,单药为628美元和53.8%;ICER为每挽救一个生命年65美元,结论认为联合方案具成本效果。

要点

  • 氟康唑联合氟胞嘧啶较单药可降低10周死亡率,且增量成本效果比低。
  • 在当前氟胞嘧啶价格下,联合方案每挽救生命年成本为65美元。
  • 广泛可及联合方案可能显著降低非洲HIV感染者隐球菌性脑膜炎死亡率。

核心结论

  • 在非洲,氟康唑联合氟胞嘧啶治疗隐球菌性脑膜炎具有成本效果,广泛可及可望显著降低HIV感染者死亡率。

研究设计与样本

  • 基于ACTA试验的有效性与赞比亚站点成本分析,氟康唑单药有效性来自连续入组队列,采用增量成本效果比及概率敏感性分析。

主要发现

  • 联合方案每例平均费用847美元(95%CI 776-927),单药628美元(95%CI 557-709)。
  • 联合方案10周死亡率35.1%(95%CI 28.9-41.7%),单药53.8%(95%CI 43.1-64.1%)。
  • 当前氟胞嘧啶价格每500mg 1.30美元时,ICER为每挽救生命年65美元(95%CI 28-208)。
  • 氟胞嘧啶降至每500mg 0.80至0.40美元时,ICER为每挽救生命年44至28美元。

关键数值与推荐

  • 成本效果以每挽救一个生命年的增量成本效果比衡量。
  • 氟胞嘧啶价格每500mg 1.30美元时ICER为65美元/生命年(95%CI 28-208)。

临床怎么用

  • 在非洲资源有限地区,若氟胞嘧啶可及,可优先考虑氟康唑联合氟胞嘧啶替代氟康唑单药治疗隐球菌性脑膜炎。

局限性

  • 成本数据主要来自赞比亚站点,有效性来自非随机队列比较,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality from cryptococcal meningitis remains very high in Africa. In the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly than 2 weeks of amphotericin-based regimens. However, many African settings treat with FLU monotherapy, and the cost-effectiveness of adding 5FC to FLU is uncertain. METHODS: The effectiveness and costs of FLU+5FC were taken from ACTA, which included a costing analysis at the Zambian site. The effectiveness of FLU was derived from cohorts of consecutively enrolled patients, managed in respects other than drug therapy, as were participants in ACTA. FLU costs were derived from costs of FLU+5FC in ACTA, by subtracting 5FC drug and monitoring costs. The cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cost-effectiveness ratio (ICER). A probabilistic sensitivity analysis assessed uncertainties and a bivariate deterministic sensitivity analysis examined the impact of varying mortality and 5FC drug costs on the ICER. RESULTS: The mean costs per patient were US $847 (95% confidence interval [CI] $776-927) for FLU+5FC, and US $628 (95% CI $557-709) for FLU. The 10-week mortality rate was 35.1% (95% CI 28.9-41.7%) with FLU+5FC and 53.8% (95% CI 43.1-64.1%) with FLU. At the current 5FC price of US $1.30 per 500 mg tablet, the ICER of 5FC+FLU versus FLU alone was US $65 (95% CI $28-208) per life-year saved. Reducing the 5FC cost to between US $0.80 and US $0.40 per 500 mg resulted in an ICER between US $44 and US $28 per life-year saved. CONCLUSIONS: The addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in Africa and, if made available widely, could substantially reduce mortality rates among human immunodeficiency virus-infected persons in Africa.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shiri T, Loyse A, Mwenge L, et al. Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. Clin Infect Dis. 2020. PMID: 30816418. doi:10.1093/cid/ciz163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。